Voya Investment Management LLC Cuts Position in Edwards Lifesciences Co. (NYSE:EW)

Voya Investment Management LLC decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 30.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,335,938 shares of the medical research company's stock after selling 576,083 shares during the quarter. Voya Investment Management LLC owned 0.23% of Edwards Lifesciences worth $98,899,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Crowley Wealth Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $26,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $30,000. Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences in the 4th quarter worth $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at $54,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on EW. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $79.45.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the sale, the vice president now directly owns 47,206 shares of the company's stock, valued at approximately $3,295,450.86. This represents a 16.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the transaction, the chief financial officer now directly owns 30,387 shares in the company, valued at approximately $2,153,526.69. This represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,853 shares of company stock worth $5,163,062. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Down 0.6 %

Shares of EW stock traded down $0.49 during trading hours on Monday, reaching $75.55. 5,001,893 shares of the stock were exchanged, compared to its average volume of 4,990,402. The business's fifty day moving average is $70.94 and its two-hundred day moving average is $71.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $44.41 billion, a P/E ratio of 10.84, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company's revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.66 EPS. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.